Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.
Antibody-mediated rejection (AbAR) is increasingly recognized in the renal allograft population, and successful therapeutic regimens have been developed to prevent and treat AbAR, enabling excellent outcomes even in patients highly sensitized to the donor prior to transplant. It has become critical to develop standardized criteria for the pathological diagnosis of AbAR. This article presents international consensus criteria for and classification of AbAR developed based on discussions held at the Sixth Banff Conference on Allograft Pathology in 2001. This classification represents a working formulation, to be revisited as additional data accumulate in this important area of renal transplantation.
Racusen
Lorraine C
LC
The Johns Hopkins University School of Medicine, Baltimore, MD, USA. lracusen@jhmi.edu
Colvin
Robert B
RB
Solez
Kim
K
Mihatsch
Michael J
MJ
Halloran
Philip F
PF
Campbell
Patricia M
PM
Cecka
Michael J
MJ
Cosyns
Jean-Pierre
JP
Demetris
Anthony J
AJ
Fishbein
Michael C
MC
Fogo
Agnes
A
Furness
Peter
P
Gibson
Ian W
IW
Glotz
Denis
D
Hayry
Pekka
P
Hunsickern
Lawrence
L
Kashgarian
Michael
M
Kerman
Ronald
R
Magil
Alex J
AJ
Montgomery
Robert
R
Morozumi
Kunio
K
Nickeleit
Volker
V
Randhawa
Parmjeet
P
Regele
Heinz
H
Seron
Daniel
D
Seshan
Surya
S
Sund
Stale
S
Trpkov
Kiril
K
D006084:Graft Rejection / Q000145:classification* / Q000276:immunology* / Q000473:pathology; D006801:Humans; D016030:Kidney Transplantation